← Eichor
Study identifier: NCT04425434 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma

Condition: Retinoblastoma  ·  Sponsor: French Africa Pediatric Oncology Group

PhaseN/A
Planned participants3000
Who can joinAll sexes, N/A to 18 Years
Healthy volunteersNo

About this study

As the survival of children with retinoblastoma in high income countries is higher than 95% including the bilateral forms this study hopes to improve the outcome in low income countries in Africa by improving early diagnosis and early implementation of this protocol of therapeutic recommendations for treatment.

This description comes directly from the study's public registry record.

Talk to the study team

KARIM Mr ASSANI, Dr.  ·  00243971359726  ·  drassanik@gmail.com

BRENDA Ms MALLON, MSc  ·  0033142115411  ·  brenda.mallon@gustaveroussy.fr

Always discuss trial participation with your own doctor first.

Locations (7)

Hopital Yalgado OuedraogoOuagadougou, Burkina FasoRecruiting
CHU de Treichville à ABIDJANAbidjan, Côte d’IvoireRecruiting
CUK (Cliniques Universitaires de Kinshasa)Kinshasa, Kinshasa City, Democratic Republic of the CongoRecruiting
Cliniques Universitaires de Lubumbashi (CUL)Lubumbashi, Democratic Republic of the CongoRecruiting
HJRA, Hôpital universitaire Joseph Ravoahangy AndrianavalonaAntananarivo, Ampefiloha, MadagascarRecruiting
CHU Gabriel Touré (HGT)Bamako, MaliRecruiting
Hôpital Aristide Le Dantec,Dakar, SenegalRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04425434